Alofisel®▼ (darvadstrocel) shows clinical remission rate at six-months in the real-world inspire study interim analysis consistent with the pivotal clinical admire-cd study1,2

Osaka, japan & cambridge, massachusetts--(business wire)--takeda (tse:4502/nyse:tak) today announced the first six-month interim analysis results from inspire, in which clinical remission* was observed in 65% of patients in both cohorts who were evaluated at 6 months.1 inspire is a european, observational, multicenter, post-approval, open-enrollment study (eupas24267) evaluating the real-world effectiveness and safety of alofisel (darvadstrocel) in patients with crohn's disease (cd) and complex
TAK Ratings Summary
TAK Quant Ranking